Fosmidomycin, a novel chemotherapeutic agent for malaria. - Test2 - elhamkhani - TriplyDB

Fosmidomycin, a novel chemotherapeutic agent for malaria.

Fosmidomycin, a novel chemotherapeutic agent for malaria.

http://www.wikidata.org/entity/Q34823125

about

Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria The MB2 gene family of Plasmodium species has a unique combination of S1 and GTP-binding domains Genomics research and malaria control: great expectations Genomics-enabled discovery of phosphonate natural products and their biosynthetic pathways Structures of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase provide new insights into catalysis Structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in a quaternary complex with a magnesium ion, NADPH and the antimalarial drug fosmidomycin Structural studies on Mycobacterium tuberculosis DXR in complex with the antibiotic FR-900098 Molecular basis of fosmidomycin's action on the human malaria parasite Plasmodium falciparum Alternatives to currently used antimalarial drugs: in search of a magic bullet New Insight into Isoprenoids Biosynthesis Process and Future Prospects for Drug Designing in Plasmodium An update on the rapid advances in malaria parasite cell biology.Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.Antimalarial compounds in Phase II clinical development.Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii.Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum Comparative cell wall core biosynthesis in the mycolated pathogens, Mycobacterium tuberculosis and Corynebacterium diphtheriae.Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria.Parasite plastids: approaching the endgame.The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs.A whole-cell phenotypic screening platform for identifying methylerythritol phosphate pathway-selective inhibitors as novel antibacterial agents.A closer look at the spectroscopic properties of possible reaction intermediates in wild-type and mutant (E)-4-hydroxy-3-methylbut-2-enyl diphosphate reductase.The global pipeline of new medicines for the control and elimination of malaria Prospects for the treatment of drug-resistant malaria parasites.Assessment of safety of the major antimalarial drugs.Prodrugs for the treatment of neglected diseases.FR-900098, an antimalarial development candidate that inhibits the non-mevalonate isoprenoid biosynthesis pathway, shows no evidence of acute toxicity and genotoxicity Biochemistry of the non-mevalonate isoprenoid pathway.Emerging drugs for malaria.Targeting apicoplasts in malaria parasites.Viable screening targets related to the bacterial cell wall.From crystal to compound: structure-based antimalarial drug discovery.Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials.MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis.QSAR based predictive modeling for anti-malarial molecules.Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin.Treating malaria in pregnancy in developing countries: priorities in clinical research and drug development.

P2860

Q21034149-3E8D2156-2DFF-41C4-AC61-5E5EA1C186B7 Q22330767-AF7031D9-2DAD-4E15-9ABC-708D58485D75 Q24680404-F65C803B-E7D2-47AB-9D22-61163DABAF42 Q24794216-4B78B570-8DD2-4734-8EE8-E2A6873FDCE3 Q24806742-A8118793-2655-4AED-93AB-897BDE1F6ABA Q26864667-0AF4FB3D-5172-4889-86F7-2093607FF282 Q27644732-02BC17FC-1A40-4226-90B7-1F25177A4979 Q27645328-3F0B377A-ACE2-4186-8E65-57BAE24FA2BC Q27676911-17369E0C-5411-4A2A-BDA1-2343563587D5 Q27677409-3A483905-BEB3-4C2D-AB0B-83B9C48F9EF8 Q28070398-225D792C-1915-4EBA-82F5-EC1CACE7B6D8 Q28078674-EB8B1339-4A28-4382-925B-B48EE5A7AD97 Q33905946-85988B80-7E78-4A63-ADC5-CD1D7EDB51D3 Q33935493-5681C64D-1BB8-4334-925B-5BE8F60CA089 Q34456807-7DF6CCF5-4A66-4502-87A5-13F60673FDFB Q35102319-1E6CDF5B-92A7-4090-9BCD-D2A4D7D55623 Q35635628-A1B8B215-823D-46CD-8D19-F1192554E6A4 Q35756648-56916171-F57E-4DE2-A813-7BB3E7C6A602 Q35759028-82E1E168-909D-4AD7-B9CC-A8C1043C1B72 Q35850868-DDD9A84B-13C2-4BA5-A838-A20DD917F152 Q36018812-246E2BA2-DBDC-4601-938B-7286E4F907C3 Q36052586-03C70006-8C6F-46A1-BC5A-550AAEA8318E Q36066272-DE2084B8-88EB-4D98-A259-FC92AC75661D Q36172371-F99794FA-E1DF-4DC1-828C-0D8729F288A4 Q36185966-928EABCE-2E80-4E3D-A98A-D996FB134A9E Q36320249-62CFD95B-6539-418E-84CA-7035ED85D0F7 Q36895758-7FE9BB36-797A-401F-ADA1-1F77075E8114 Q36945007-FE380717-4E13-4885-935D-7F2928F3DEF2 Q37157236-CB907257-84A9-4A33-8323-C0F94080CC1C Q37189932-C375B6F7-815E-4394-8150-C901E62FBEC2 Q37899789-019082BC-BB6F-4F50-96B6-CA581F90321B Q38027179-2708B738-0BD1-4138-AC78-8BD75800DCAC Q38066563-1EE8B428-53E9-4328-91C8-7469384F2580 Q38070780-B839FC74-9914-412A-8DF4-E9B47A0CFE9F Q38227796-8B1F0A8E-FC7B-4863-A63F-B5BA506A2029 Q38558100-6B8A5504-8AAC-4FEB-A4AA-F0FDCBF7C79D Q38615212-6770EA1F-AB3D-42CF-B5CC-EEE98AE247EC Q38687538-56BF190A-266F-485B-9DE0-D716B94FFFF3 Q38839163-6E9D3E91-0360-4412-9ACB-64384E727EA0 Q39546704-3EB8C5FF-1316-4ACF-A184-185796171C6D

P2860

Fosmidomycin, a novel chemotherapeutic agent for malaria.

http://www.wikidata.org/entity/Q34823125

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@ast

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@en

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@nl

type

label

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@ast

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@en

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@nl

prefLabel

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@ast

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@en

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@nl

P1433

Q34823125-C7A9F7BA-F390-4A05-98CE-13BF908CAACF

P1476

Q34823125-91CE60D9-ABC8-4933-989C-FDB685C3C20C

P2093

Q34823125-1DAF6737-1856-46B2-972C-2737F07D6FDC

Q34823125-6267E8F2-D050-429D-B0BC-BA504E1B0926

Q34823125-7C0AE4F1-8506-4113-A359-93FE456987A9

Q34823125-AB8FFB6F-4876-40F0-AA03-9AA00F4835DD

Q34823125-C12E0725-08C4-45A5-805A-5E094F8DC906

Q34823125-C301A1F2-BC35-4EEF-9164-7DA30E67D04A

Q34823125-C884FE2B-F4E2-4DCD-8D15-D7D827FE5977

Q34823125-D86EB4D0-D2C8-4DB9-B91A-941F0B7A9134

P2860

Q34823125-037EF4B9-AA9E-4C3F-B3A3-D2394A1C0D96

Q34823125-074611E9-2F01-4D11-8954-184E3B34A3CD

Q34823125-0C0CCBE0-CBDD-4E91-92CA-048CDA6AE31E

Q34823125-17B63D33-8F03-4A32-A344-9600E7B854A8

Q34823125-4B8F7321-0C4F-48D8-9555-D0C7144AB022

Q34823125-5CABE63B-3EF7-45AC-9BC3-4EBE6272C805

Q34823125-8C1D6E08-5042-452E-A350-8A5101059CE9

Q34823125-A7C07714-B5BB-4CD6-874D-ADCD3D331CE7

Q34823125-AA11A7E8-1DA0-403E-BF78-ABC640B4D58F

Q34823125-ABE6BBF5-5E24-4CA5-8D8C-37E835ECE87C

P304

Q34823125-CAD461EA-8A86-43C0-87D0-B76FFEA22894

P31

Q34823125-F16CCC2B-66B8-420C-A00C-1400C3CEDD38

P356

Q34823125-049ECCC7-6030-4953-8431-0CD327690A23

P407

Q34823125-F23E6C98-C9CF-45CD-9A6F-6F51577CD511

P433

Q34823125-EC12B134-9A2C-4829-9DC4-72AE04423F18

P478

Q34823125-C335C4DC-7718-41E8-9B8E-7C3DD0B0104B

P50

Q34823125-028C6DEB-F53A-4906-A380-EF6C5795CE12

Q34823125-193A083A-2DD6-4309-9A97-114401424BF2

P577

Q34823125-07679ECB-EF0D-496D-AD52-644219C17915

P5875

Q34823125-6C0D0BA9-9D09-4731-8D77-2288A059ED98

P698

Q34823125-08777F77-DCE7-47D0-8EEB-79CA0E708422

P921

Q34823125-6DEF0278-724B-434F-9CD7-EC15A028B831

Q34823125-C19B7871-CA78-471D-9664-96322A95355D

Q34823125-EEBC2874-1E9E-49E6-A69A-99D76D376245

Q34823125-F6EB77F0-EDC3-4732-9235-B4DDD62FD1ED

P932

Q34823125-11E63575-5D5A-4636-9451-52E00D340386

P356

AAC.47.2.735-738.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Fosmidomycin, a novel chemotherapeutic agent for malaria.

@en

P2093

Andreas Schindler

http://www.w3.org/2001/XMLSchema#string

David Hutchinson

http://www.w3.org/2001/XMLSchema#string

Hassan Jomaa

http://www.w3.org/2001/XMLSchema#string

Jochen Wiesner

http://www.w3.org/2001/XMLSchema#string

Martin Hintz

http://www.w3.org/2001/XMLSchema#string

Michel Anoumou Missinou

http://www.w3.org/2001/XMLSchema#string

Ronnatrai Ruangweerayut

http://www.w3.org/2001/XMLSchema#string

Thomas Baranek

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs

Delaying antimalarial drug resistance with combination chemotherapy.

Medical need, scientific opportunity and the drive for antimalarial drugs.

Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine.

Biochemistry of polyisoprenoid biosynthesis.

Merozoite surface antigen 1 and 2 genotypes and rosetting of Plasmodium falciparum in severe and mild malaria in Lambaréné, Gabon.

Mosquito distribution and entomological inoculation rates in three malaria-endemic areas in Gabon.

Drug sensitivity of Plasmodium falciparum in Gabon. Activity correlations between various antimalarials.

Effects of tetracycline against chloroquine-resistant and chloroquine-sensitive Plasmodium falciparum.

Antimalarial effects of tetracyclines in man.

P304

735-738

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.2.735-738.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Peter Gottfried Kremsner

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8525786

http://www.w3.org/2001/XMLSchema#string

P698

12543685

http://www.w3.org/2001/XMLSchema#string

P921

fosmidomycin transport

fosmidomycin transporter activity

P932

151759

http://www.w3.org/2001/XMLSchema#string